2021
Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer
Low J, Huang Y, Sooi K, Ang Y, Chan Z, Spencer K, Jeyasekharan A, Sundar R, Goh B, Soo R, Yong W. Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer. International Journal Of Cancer 2021, 149: 169-176. PMID: 33634869, PMCID: PMC9545741, DOI: 10.1002/ijc.33534.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerProgression-free survivalCell lung cancerFood and Drug AdministrationOverall survivalTreatment of advanced non-small cell lung cancerLung cancerDose of pembrolizumabImmune-related toxicitiesEffectiveness of pembrolizumabWeight-based dosingRetrospective observational studyNational University HospitalDegrees of cost savingsCost-minimisation analysisFixed doseSurvival outcomesAsian patientsNo significant differencePembrolizumabOncogenic driversSingle agentLow dosesRandomised trials
2019
First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors
Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja E, Nishio M. First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors. Molecular Cancer Therapeutics 2019, 18: molcanther.0831.2018. PMID: 30679388, DOI: 10.1158/1535-7163.mct-18-0831.Peer-Reviewed Original ResearchConceptsGastrointestinal stromal tumorsPreliminary antitumor efficacyDose-escalation phaseAdvanced solid tumorsSolid tumorsTAS-116Eye disordersEscalation phaseFirst-in-human phase I studyPretreated gastrointestinal stromal tumoursHsp90 inhibitorsTreatment-related adverse eventsNon-small cell lung cancerFirst-in-human studyOral HSP90 inhibitorPhase I studyCell lung cancerPartial responseStromal tumorsDose proportionalityAntitumor efficacySafety profileSystemic exposureAdverse eventsLung cancer
2018
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
Basu B, Krebs M, Sundar R, Wilson R, Spicer J, Jones R, Brada M, Talbot D, Steele N, Garces A, Brugger W, Harrington E, Evans J, Hall E, Tovey H, de Oliveira F, Carreira S, Swales K, Ruddle R, Raynaud F, Purchase B, Dawes J, Parmar M, Turner A, Tunariu N, Banerjee S, de Bono J, Banerji U. Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals Of Oncology 2018, 29: 1918-1925. PMID: 30016392, PMCID: PMC6158767, DOI: 10.1093/annonc/mdy245.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBenzamidesCarcinoma, Non-Small-Cell LungDrug Administration ScheduleFemaleHumansLung NeoplasmsMaleMaximum Tolerated DoseMechanistic Target of Rapamycin Complex 1Mechanistic Target of Rapamycin Complex 2Middle AgedMorpholinesOvarian NeoplasmsPaclitaxelPhosphorylationProtein Kinase InhibitorsPyrimidinesResponse Evaluation Criteria in Solid TumorsRibosomal Protein S6 KinasesConceptsHigh-grade serous ovarian cancerSquamous non-small-cell lung cancerNon-small-cell lung cancerWeekly paclitaxelOvarian cancerSchedule ALung cancerIntermittent scheduleRecommended phase II doseResponse rateDose-escalated armPhase II doseRECIST response rateDose-limiting toxicityProgression-free survivalAdvanced solid tumorsPhase I trialSerous ovarian cancerResistance to chemotherapyP-S6K levelsConsecutive daysII doseDose escalationExpansion cohortI trial
2017
Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer
Dolly S, Collins D, Sundar R, Popat S, Yap T. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs 2017, 77: 813-827. PMID: 28378229, DOI: 10.1007/s40265-017-0732-2.Peer-Reviewed Educational MaterialsMeSH KeywordsAntineoplastic AgentsBiomarkers, TumorCarcinoma, Non-Small-Cell LungDrug DiscoveryDrug Resistance, NeoplasmHumansLung NeoplasmsMolecular Targeted TherapyConceptsAnaplastic lymphoma kinaseEpidermal growth factor receptorDevelopment of molecular-targeted agentsAdvent of immune checkpoint inhibitorsNon-small-cell lung cancerPredictive biomarkers of responseEmergence of acquired resistanceTreatment approachesAdvanced NSCLC patientsImmune checkpoint inhibitorsProgression-free survivalMolecular targeted agentsBiomarkers of responseNon-small-cellTreatment of patientsCancer-related mortalityGrowth factor receptorMutation-specific inhibitorsAnti-tumor agentsCheckpoint inhibitorsNSCLC patientsGene aberrationsDownstream signaling blockadePredictive biomarkersMolecular subtypes
2014
Immunotherapy in the treatment of non-small cell lung cancer
Sundar R, Soong R, Cho B, Brahmer J, Soo R. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer 2014, 85: 101-109. PMID: 24880938, PMCID: PMC4332778, DOI: 10.1016/j.lungcan.2014.05.005.Peer-Reviewed Educational MaterialsMeSH KeywordsAnimalsAntibodies, MonoclonalCarcinoma, Non-Small-Cell LungCarrier ProteinsCostimulatory and Inhibitory T-Cell ReceptorsHumansImmunotherapyLung NeoplasmsProtein BindingConceptsImmune response to tumorsTreatment of non-small cell lung cancerNon-small cell lung cancerProlonged clinical responsesImmune checkpoint modulatorsImmune checkpoint pathwaysPD-L1 inhibitorsResponse to tumorsCell lung cancerCTLA-4PD-1PD-L1Tolerable toxicityTumor immunosurveillanceCheckpoint modulatorsCo-stimulatoryCo-inhibitoryClinical responseImmunotherapeutic agentsPredictive biomarkersImmune destructionLung cancerTreatment selectionImmune systemInhibitory molecules